scholarly journals Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3218
Author(s):  
Gian Paolo Caviglia ◽  
Michela Ciruolo ◽  
Maria Lorena Abate ◽  
Patrizia Carucci ◽  
Emanuela Rolle ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Diagnostic Accuracy ◽  
Vitamin K ◽  
Area Under The Curve ◽  
Alpha Fetoprotein ◽  
Rank Test ◽  
Viral Etiology ◽  
Serum Samples ◽  
Serum Alpha Fetoprotein

International guidelines recommend the use of ultrasound as a surveillance tool for hepatocellular carcinoma (HCC) in patients with cirrhosis, while the role of serum biomarkers is still debated. We investigated serum alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist II (PIVKA-II) and glypican-3 (GPC-3) diagnostic accuracy for HCC detection and prediction in patients with liver cirrhosis of viral etiology under surveillance. A total of 349 patients (200 cirrhosis and 149 HCC) were enrolled. The 200 patients with cirrhosis consisted of 114 patients still HCC-free after 36 months of follow-up and 86 patients that developed HCC after 13.8 (11.0–19.8) months. AFP, PIVKA-II and GPC-3 were measured in serum samples collected at tumor diagnosis in the 149 patients with HCC, and at the beginning of follow-up in the 200 patients with cirrhosis. The higher performance for HCC detection was observed for PIVKA-II (area under the curve (AUC) = 0.790), followed by AFP (AUC = 0.737) and GPC-3 (AUC = 0.637); the combination of AFP + PIVKA-II improved the diagnostic accuracy to AUC = 0.822. Serum PIVKA-II values, but not AFP and GPC-3, were significantly higher in the 86 cirrhotics that developed HCC compared with the 114 cirrhotics still HCC-free after 36 months of follow-up (p = 0.020). PIVKA-II ≥ 55 mAU/mL allowed to identify patients with cirrhosis at higher risk of HCC development (Log-rank test, p < 0.001; adjusted Hazard Ratio = 1.99, p = 0.001). In conclusion, the measurement of PIVKA-II in patients with cirrhosis may be useful to tailor personalized surveillance strategies.

Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma

2000 ◽  
Vol 95 (4) ◽  
pp. 1036-1040 ◽  
Author(s):  
Motoyasu Ishii ◽  
Hiroko Gama ◽  
Nobuyuki Chida ◽  
Yoshiyuki Ueno ◽  
Haruhide Shinzawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Vitamin K ◽  
Alpha Fetoprotein ◽  
Simultaneous Measurements ◽  
Serum Alpha Fetoprotein

scholarly journals Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma

2016 ◽  
Vol 44 (6) ◽  
pp. 1414-1423 ◽  
Author(s):  
Aiying Zhang ◽  
Chengzeng Yin ◽  
Zhenshun Wang ◽  
Yonghong Zhang ◽  
Yuanshun Zhao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Protein Microarray ◽  
Characteristic Curve ◽  
Alpha Fetoprotein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Control Subjects ◽  
Serum Alpha Fetoprotein ◽  
Healthy Control ◽  
Fluorescence Protein

Objective To develop a simple, effective, time-saving and low-cost fluorescence protein microarray method for detecting serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC). Method Non-contact piezoelectric print techniques were applied to fluorescence protein microarray to reduce the cost of prey antibody. Serum samples from patients with HCC and healthy control subjects were collected and evaluated for the presence of AFP using a novel fluorescence protein microarray. To validate the fluorescence protein microarray, serum samples were tested for AFP using an enzyme-linked immunosorbent assay (ELISA). Results A total of 110 serum samples from patients with HCC ( n = 65) and healthy control subjects ( n = 45) were analysed. When the AFP cut-off value was set at 20 ng/ml, the fluorescence protein microarray had a sensitivity of 91.67% and a specificity of 93.24% for detecting serum AFP. Serum AFP quantified via fluorescence protein microarray had a similar diagnostic performance compared with ELISA in distinguishing patients with HCC from healthy control subjects (area under receiver operating characteristic curve: 0.906 for fluorescence protein microarray; 0.880 for ELISA). Conclusion A fluorescence protein microarray method was developed for detecting serum AFP in patients with HCC.

Pattern Analysis of Serum alpha-fetoprotein in the Early Diagnosis of Hepatocellular Carcinoma in Liver Cirrhosis

1988 ◽  
Vol 3 (3) ◽  
pp. 172-176 ◽  
Author(s):  
A. Arrigoni ◽  
A. Andriulli ◽  
T. Gindro ◽  
P. Piantino ◽  
L. Capussotti ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Liver Tumors ◽  
Alpha Fetoprotein ◽  
Cutoff Point ◽  
Surveillance Program ◽  
Unique Role ◽  
Early Expression ◽  
Serum Alpha Fetoprotein

In a surveillance program for hepatocellular carcinoma (HCC), serum alpha-fetoprotein (AFP) was determined every 4 months in 164 patients with liver cirrhosis. Ultrasonography (US) was performed yearly or as dictated by abnormal AFP levels. During a follow-up of 32.5 ± 20.8 months HCC was identified by US in 16 patients. In 9 of them the AFP levels rose steadily over 4 months, increasing 7, 8 and 12 months in 3 cases before the lesion became detectable by US. In 4 patients tumors developed despite persistently normal AFP levels. Nine more patients showed abnormal fluctuations of AFP but HCC was not detected. AFP sensitivity was higher at a low cutoff point (40 ng/ml) while specificity of the test appeared higher at the 200 ng/ml cutoff point. An AFP value rising steeply over a few months appeared more reliable than a fixed preset threshold in indicating carcinomatous transformation. Screening for AFP can be expected to uncover about 3/4 of HCC developing in cirrhotics with few false-positive reactions. The test may have a unique role in identifying a subset of liver tumors whose early expression is AFP production.

Role of Alpha-Fetoprotein in Selection of Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation: Must we Reconsider it?

2011 ◽  
Vol 26 (3) ◽  
pp. 153-159 ◽  
Author(s):  
Quirino Lai ◽  
Alfonso W. Avolio ◽  
Tommaso M. Manzia ◽  
Salvatore Agnes ◽  
Giuseppe Tisone ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Multivariate Logistic Regression Analysis ◽  
Alpha Fetoprotein ◽  
Rank Test ◽  
Recurrence Prediction ◽  
Serum Alpha Fetoprotein ◽  
Selection Of Patients ◽  
Hcc Recurrence ◽  
Selection Of

Background Milan criteria (MC) represent the most commonly adopted criteria for the selection of patients with hepatocellular carcinoma (HCC) waiting for liver transplantation (LT). However, MC are exclusively based on morphological aspects. The aim of the present study was to evaluate pre-LT–detectable biological parameters, to compare them with morphological ones in terms of tumor recurrence prediction and patient survival. Methods A cohort of 153 consecutive adult patients who underwent LT for HCC on cirrhosis from January 1999 to March 2009 was retrospectively analyzed. Results HCC recurrence was observed in 12 patients (7.8%). At multivariate logistic regression analysis, serum alpha-fetoprotein (AFP) was the unique independent negative risk factor for the development of HCC recurrence (odds ratio 2.0, p=0.03). Adopting a cutoff value of 210 ng/mL, patients who presented serum AFP ≥210 ng/mL showed a 5-year survival rate of 23.3% versus 76.2% observed in patients with pre-LT serum AFP <210 ng/mL (log-rank test: <0.0001). Conclusions In our experience, AFP was the strongest predictor of HCC recurrence, stronger than tumor morphology. AFP could ameliorate the selection of LT candidates. Further studies to evaluate the combination of morphological and biological criteria are needed.

Decreasing trend of serum alpha-fetoprotein level in hepatocellular carcinoma

2021 ◽  
Author(s):  
Aarshi Vipani ◽  
Marie Lauzon ◽  
Michael Luu ◽  
Lewis R. Roberts ◽  
Amit G. Singal ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Alpha Fetoprotein ◽  
Serum Alpha Fetoprotein
Sign in / Sign up

Export Citation Format

Share Document